William C. Shakespeare Ph.D.
Net Worth

Last updated:

What is William C. Shakespeare Ph.D. net worth?

The estimated net worth of Dr. William C. Shakespeare Ph.D. is at least $1,292,960 as of 6 Nov 2023. He has received compensation worth at least $1,292,960 in Theseus Pharmaceuticals, Inc..

What is the salary of William C. Shakespeare Ph.D.?

Dr. William C. Shakespeare Ph.D. salary is $323,240 per year as Co-Founder and Pres of R&D in Theseus Pharmaceuticals, Inc..

How old is William C. Shakespeare Ph.D.?

Dr. William C. Shakespeare Ph.D. is 62 years old, born in 1963.

What stocks does William C. Shakespeare Ph.D. currently own?

As insider, Dr. William C. Shakespeare Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Theseus Pharmaceuticals, Inc. (THRX) Co-Founder and Pres of R&D 388,949 $0 $0

What does Theseus Pharmaceuticals, Inc. do?

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

THRX logo
THRX
Theseus Pharmaceuticals, Inc.

William C. Shakespeare Ph.D. insider trading

Theseus Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (right to buy) 251,084 $0.32 $80,347
Option
Common Stock 251,084 $0.32 $80,347
Purchase
Common Stock 625 $16 $10,000

Theseus Pharmaceuticals key executives

Theseus Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. David C. Dalgarno Ph.D. (67) Co-Founder, Senior Vice President & Chief Technology Officer
  • Dr. Iain D. Dukes D.Phil., M.A., Ph.D. (67) Co-Founder & Chairman
  • Dr. Victor M. Rivera Ph.D. (61) Co-Founder, Senior Vice President & Chief Scientific Officer
  • Dr. William C. Shakespeare Ph.D. (62) Co-Founder and Pres of R&D